| OS | Osteosarcoma |
| CDDP | Cisplatin |
| ROS | Reactive oxygen species |
| DNA | Deoxyribonucleic acid |
| DMEM | Dulbecco’s modified Eagle’s medium |
| FBS | Fetal bovine serum |
| FITC | Fluorescein isothiocyanate |
| PI | Propidium iodide |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide |
| DMSO | Dimethyl sulfoxide |
| PBS | Phosphate-buffered saline |
| PE | Plating efficiency |
| SF | Surviving fraction |
| DHR-123 | Dihydrorhodamine-123 |
| MCS | Multicellular spheroids |
| FDA | Fluorescein diacetate |
| s.c. | Injected subcutaneously |
| i.p. | Intraperitoneal |
| TGR | Tumor growth rates |
| H&E | Hematoxylin and eosin |
| HPF | High-power field |
| NA | Necrotic area |
| VA | Viable area |
| TNR | Tumor necrotic rate |
| ATNR | Adjusted tumor necrotic rate |
| RTGR | Relative tumor growth rates |
| GOT | Aspartate aminotransferase |
| ALT | Alanine aminotransferase |
| SEM | Standard error of the mean |
| SI | Selectivity index |
| o-HVA | 2-hydroxy-3-methoxybenzaldehyde |
| MCR | Multicellular resistance |
| ECM | Extracellular matrix |